Startseite Kongressberichte & Archiv 2021 ASCO Annual Meeting Gynaecological Cancer Gynecologic Cancer
Felix Blanc-Durand, Elisa Yaniz, Catherine Genestie, et al.
The study authors evaluated a novel functional assay of HR functionality in advanced EOC. They demonstrated the following results:
- The assay requires minimal tissue and yields contributive results in 90% of cases.
- EOC has high levels of basal DNA damage, 55% fail to recruit RAD51 foci during S/G2 cell cycle phase.
- These RAD51-deficient EOC have improved outcomes after neoadjuvant platinum therapy.
- The RAD51 assay also identified a small subset of RAD51-high BRCAmut tumors with a poor platinum response.
Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial.
Patricia Pautier, Philipp Harter, Carmela Pisano, et al.
The study authors conclude that In the PAOLA-1 study, maintenance olaparib plus bevacizumab provided a progression-free survival and PFS2 benefit over placebo plus bevacizumab in HRD+ patients, irrespective of FIGO stage and residual disease after upfront surgery. Clinical trial information: NCT02477644
Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study.
Cara Amanda Mathews, Fiona Simpkins, Karen Anne Cadoo, et al.
The study authors conclude with their final analysis that 18-month overall survival ranged from 60–88% across the 4 cohorts.
The 18-month overall survival rate was highest in the BRCAm cohorts (similar overall survival in g and sBRCAm); among patients without a BRCAm, 18-month overall survival was highest in the HRD +ve cohort.
Compared with the primary analysis and with prior olaparib studies there were no new safety signals observed. Clinical trial information: NCT02983799
Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.
Stephanie L. Wethington, Payal D Shah, Lainie P. Martin, et al.
The study authors conclude that olaparib plus ceralasertib is well tolerated and shows clinical activity in recurrent HRD HGSOC after progressing on prior PARPi. This is the first time a study is suggesting the potential of ATR inhibitors to overcome PARPi resistance in an HRD patient population. Clinical trial information: NCT03462342
Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.
Amit M. Oza, Alla Sergeevna Lisyanskaya, Alexander A. Fedenko, et al.
The study authors conclude that that rucaparib is a reasonable treatment option for heavily pretreated patients across all platinum sensitivity subgroups. There were no new safety signals compared with prior rucaparib studies. Clinical trial information: NCT02855944
Niraparib efficacy and safety in patients with BRCA mutated (BRCAm) ovarian cancer: Results from three phase 3 niraparib trials.
Antonio Gonzalez Martin, Ursula A. Matulonis, Jacob Korach, et al.
Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).
Rachel N. Grisham, Ignace Vergote, Susana N. Banerjee, et al.
The study authors conclude that higher response rates and longer progression-free survival were seen in those patients with LGSOC treated with binimetinib who harbored MAPK mutations, most commonly in KRAS. However, this is a hypothesis generating analysis limited by multiple testing. The authors recommend, that somatic tumor testing should be routinely performed in patients with recurrent LGSOC to aid in clinical decision making. Clinical trial information: NCT01849874
An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer (KGOG 3045, AMBITION).
JUNG-YUN LEE, Byoung-Gie Kim, Jae-Weon Kim, et al.
The study authors conclude that in this first biomarker-driven umbrella study in patients with platinum-resistant recurrent ovarian cancer preliminary evidence is provided on the clinical benefit of biomarker-driven targeted therapy. All regimens were manageable, and no unexpected toxicities were observed. Clinical trial information: NCT03699449
Dendritic cell vaccine (DCVAC) combined with chemotherapy (CMT) in patients with newly diagnosed epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Biomarker exploratory analysis of a phase 2, open-label, randomized, multicenter trial.
Lukas Rob, David Cibula, Pawel Knapp, et al.
The study authors conclude that an autologous immunotherapy with Dendritic-cell vaccine improved progression-free and overall survival outcomes in patients with newly diagnosed EOC. This was predominantly observed in patients with immunologically “cold” tumors, thus representing a promising treatment option in this patient population. Clinical trial information: NCT02107937
Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.
Judith Michels, François Ghiringhelli, Jean-Sebastien Frenel, et al.
The study authors conclude that the combination was well tolerated and demonstrated clinical benefit in 74% platinum resistant ovarian cancer patients with a durable response (>6 months) in 53% of patients. Clinical trial information: NCT03596281
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).
Dana M Roque, Stefania Bellone, Eric R. Siegel, et al.
The study authors conclude that their study demonstrated prognostic significance of Lynch-like versus sporadic MSI-H EC on ORR, progression-free and overall survival when treated with pembrolizumab. Clinical trial information: NCT02899793
Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial.
Qin Xu, Chuanben Chen, Yang Sun, et al.
The study authors conclude that Anlotinib - a novel multi-target tyrosine kinase inhibitor - plus sintilimab - a fully humanized, high-affinity monoclonal antibody against programmed cell death-1 (PD-1) - showed a promising efficacy with a favorable toxicity profile for patients with recurrent advanced cervical cancer. Clinical trial information: ChiCTR1900023015.